Physician profile
Amanda Humbers
NPI 1720421514
$19,281.69
in general payments reported to CMS, 2019-2025
63 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,291 · 2022: $4,253 · 2023: $4,683 · 2024: $3,769 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,737.17 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,864.17 | 2021-2025 | Nayzilam, Fintepla, Briviact |
| Novartis Pharmaceuticals Corporation | $1,371.88 | 2021-2025 | |
| Sk Life Science, INC. | $1,085.00 | 2021-2025 | Xcopri |
| Abbvie INC. | $971.00 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $843.85 | 2021-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $823.72 | 2021-2024 | Austedo Xr, Austedo, Ajovy |
| Neurocrine Biosciences, INC. | $739.49 | 2022-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $719.37 | 2021-2025 | Mavenclad |
| Pfizer INC. | $682.81 | 2021-2025 | |
| Argenx US, INC. | $665.32 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $649.21 | 2021-2025 | Nuplazid |
| Celgene Corporation | $644.39 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $584.48 | 2021-2025 | Emgality, Kisunla, Reyvow |
| Amgen INC. | $560.52 | 2021-2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $528.11 | 2022 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $527.09 | 2021 | |
| Amneal Pharmaceuticals LLC | $524.18 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Sunovion Pharmaceuticals INC. | $372.02 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $345.46 | 2022-2025 | |
| Biogen, INC. | $342.13 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Genzyme Corporation | $323.47 | 2021-2025 | |
| Genentech USA, INC. | $286.88 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Neurelis, INC. | $276.45 | 2021-2025 | Valtoco |
| Livanova USA, INC. | $258.86 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals LP | $256.22 | 2021-2022 | |
| Lundbeck LLC | $252.57 | 2022-2025 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $242.29 | 2022-2025 | Wakix |
| Ipsen Biopharmaceuticals, INC | $226.04 | 2021-2022 | |
| Tg Therapeutics, INC. | $206.74 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $196.97 | 2021-2023 | Qelbree |
| Banner Life Sciences, LLC | $178.00 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.09 | 2021-2025 | Hyqvia |
| Upsher-Smith Laboratories LLC | $132.87 | 2021-2022 | |
| Horizon Therapeutics Plc | $126.84 | 2022-2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $115.22 | 2022-2023 | Onpattro |
| Aquestive Therapeutics, INC. | $102.15 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $96.34 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $93.42 | 2023-2025 | Ztlido |
| Vanda Pharmaceuticals INC. | $76.13 | 2021-2025 | Ponvory |
| Nevro Corp. | $67.62 | 2023 | Senza |
| Otsuka America Pharmaceutical, INC. | $67.38 | 2023-2025 | Nuedexta, Rexulti |
| Allergan, INC. | $58.31 | 2021 | |
| Corium, LLC | $56.68 | 2022-2023 | Adlarity, Azstarys |
| Catalyst Pharmaceuticals, INC. | $56.63 | 2023-2024 | Firdapse |
| Avanir Pharmaceuticals, INC. | $47.39 | 2022 | |
| Mdd US Operations, LLC | $44.70 | 2021 | |
| Cycle Pharmaceuticals INC | $44.54 | 2024-2025 | Tascenso Odt |
| Adamas Pharmaceuticals, INC. | $42.20 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $39.68 | 2021 | |
| Csl Behring | $39.37 | 2022-2023 | Hizentra |
| Eisai INC. | $34.44 | 2023 | |
| Axsome Therapeutics, INC. | $26.48 | 2025 | Symbravo |
| Ns Pharma, INC. | $24.64 | 2022 | |
| Sumitomo Pharma America, INC. | $23.95 | 2023 | Aptiom |
| Tanabe Pharma America, INC. | $23.38 | 2024 | |
| Janssen Biotech, INC. | $20.13 | 2025 | |
| Janssen Pharmaceuticals, INC | $18.90 | 2022 | |
| Immedica Pharma US, INC. | $18.57 | 2023 | |
| Grt US Holding, INC. | $17.35 | 2021 | |
| W. L. Gore & Associates, INC. | $15.38 | 2023 | Gore Cardioform Septal Occluder |
| Kyowa Kirin, INC. | $15.03 | 2021 | |
| Avion Pharmaceuticals | $14.78 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Humbers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.